University of Texas Southwestern Medical Center Neurodevelopmental Disabilities

Topics

• Multiple Sclerosis Research Studies 126
• Glycogen Storage Diseases and Myoclonus 123
• Epilepsy research and treatment 88
• Neurogenetic and Muscular Disorders Research 71
• Muscle Physiology and Disorders 62
• Genetics and Neurodevelopmental Disorders 48
• Blood Coagulation and Thrombosis Mechanisms 30
• Neurological disorders and treatments 22
• Autoimmune Neurological Disorders and Treatments 21
• Genomics and Rare Diseases 20
• Hemoglobinopathies and Related Disorders 17
• Cardiomyopathy and Myosin Studies 16

Most cited

1. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.

   The Lancet. Neurology · 2021 · 399 citations · Susan Iannaccone

2. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.

   Nature medicine · 2022 · 263 citations · Susan Iannaccone

3. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.

   Nature medicine · 2022 · 236 citations · Susan Iannaccone

4. Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.

   JAMA neurology · 2024 · 94 citations · Benjamin Greenberg

5. Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.

   Annals of neurology · 2024 · 88 citations · Benjamin Greenberg

6. Acute flaccid myelitis: cause, diagnosis, and management.

   Lancet (London, England) · 2021 · 133 citations ·